Emphysematous pancreatitis predisposed by Olanzapine

Area of Science:

• Gastroenterology
• Endocrinology
• Pharmacology

Background:

• Olanzapine is an atypical antipsychotic used for bipolar disorder.
• Acute pancreatitis is a serious inflammation of the pancreas.
• Emphysematous pancreatitis is a rare and severe form of acute pancreatitis characterized by gas within the pancreatic tissue.

Purpose of the Study:

• To report a rare case of emphysematous pancreatitis.
• To explore the potential link between olanzapine therapy and pancreatitis.
• To discuss the predisposing factors and management of this condition.

Main Methods:

• Case report of a 32-year-old male patient.
• Clinical presentation, laboratory findings (lipase, triglycerides, blood glucose), and imaging (contrast-enhanced computed tomography - CECT).
• Management including percutaneous drainage and antibiotic irrigation.

Main Results:

• The patient developed severe abdominal pain and was diagnosed with acute pancreatitis after 2 months of olanzapine.
• Laboratory results showed elevated lipase, triglycerides, and blood glucose levels.
• CECT revealed gas within the pancreas and peripancreatic collection, consistent with emphysematous pancreatitis.

Conclusions:

• Short-term olanzapine therapy can be a predisposing factor for emphysematous pancreatitis.
• Development of diabetes, hypertriglyceridemia, and potential immunosuppression may contribute to this rare complication.
• Prompt diagnosis and management, including drainage and antibiotics, are crucial for patient outcomes.